Autologous T cells from tumor‑draining lymph nodes are activated and expanded ex vivo with patient‑specific neoantigen proteins to enrich polyclonal, neoantigen‑specific TCRs. Following lymphodepletion, the infused cells recognize neoantigen peptides presented on MHC I/II on tumor cells and mediate cytotoxic killing (perforin/granzyme) and cytokine‑driven immune responses, boosting tumor‑specific immunity and overcoming tolerance in colorectal cancer.